Who owns Eikon Therapeutics, Inc. (EIKN)? Elite investor 13F holders
3 tracked elite investors reported holding Eikon Therapeutics, Inc as of 2026-06-30, including Polen Capital Management, Renaissance Technologies LLC, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Polen Capital Management | EIKON THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 466433.00 USD | 35742.000000 | Shares | buy | Original filing |
| Renaissance Technologies LLC | EIKON THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 349701.00 USD | 26797.000000 | Shares | buy | Original filing |
| Tudor Investment | EIKON THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 195750.00 USD | 15000.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.